Something to Think About: Animal and Patient Rights

New Jersey is an interesting place to live. For the past month or so, there have been daily local newspaper reports (recently elevated to national status by the Associated Press) about a dog named Congo who was sentenced to be euthanized by a NJ judge. The story goes something like this: Gardeners (who happen to be Hispanic) show up an hour early for a landscaping job that they were slated to perform at a Princeton, NJ home. The homeowner decides that the workers arrived too early for the job (go figure) and tells them by phone to wait until he is ready for them and to not step onto his property because the dog was “still outside”. Well, as you may have guessed, after about an hour of waiting, the gardeners decide to get out of their truck anyway and one of them is attacked and seriously maimed by the family dog named Congo. The attack culminates in Congo’s arrest, having his day in court, losing his case and then being sentenced to death. Now here is where it gets interesting. The dog’s owner, who happens to be wealthy, decides to mount a campaign to prevent Congo’s pending death. The “Free Congo” movement gains enough public support and momentum to get Congo released from doggy jail pending an appeal (sort of the like the “Free the Chicago 7” movement for those of you who remember 1968).

Yesterday, there was a Congo update story in my local paper. Congo is alive and well, living with his family and wearing a muzzle when he goes outside. Nobody really knows what is going on with the guy who was mauled but that is beyond the scope of this post.  Yesterday's article was basically a rehash of the Congo epic with a spin related to immigration and immigrant rights. But, what got me thinking was this statement in the article; “ The governor’s office has received more telephone calls, e-mails, letters and faxes about Congo than any other issue since the Governor took office” (two years ago). This is in a state where its citizens recently rejected a referendum to publicly fund stem cell research and where many people (in its largest cities) do not have adequate access to healthcare or health insurance.

Personally, like NJ Governor Corzine, I do not want Congo to be euthanized (I am philosophically opposed to the death penalty). But the larger issue that ought to be addressed is:” Why can people quickly mobilize and get emotionally involved when a pet’s life is in danger and seemingly not care about the well-being of other people whose lives may also be in danger?  What about the rights of guy who was mauled and the people who suffer daily because of inadequate or no access to health care?"

Think about it and let me know.

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!!


Job Cuts at Pharma and Biotech Companies Hit Almost Record Highs in 2007

I hate to be the bearer of bad news (don’t kill the messenger) but 2007 has been rife with corporate downsizing and job layoffs. According to a post at Fierce Biotech, jobs cuts were primarily driven by “Concerns about patent expirations, falling sales due to drug safety concerns, redundancy from acquisitions and a general need to streamline operations”. The companies that have “laid-off” the most workers are:  

  1. Pfizer-10,000 
  2. Astra Zeneca-7,600 
  3. Bayer-6,100 
  4. Johnson & Johnson
  5. 5,000 Amgen-2,600

Companies that did not make the list but have quietly been laying off workers or freezing jobs include GlaxoSmithKline, Merck, Eli Lilly and Bristol-Myers Squibb.

It is not a good time to be looking for a job in the pharma or biotech industries. That said, there is always hope and let’s “hope” that 2008 is a better year for both industries.

Until next time….

Good Luck (you will need it) and Good Job Hunting!

Bristol-Myers Squibb to Announce Layoffs This Week

Rumor has it that Bristol-Myers Squibb will announce its long-awaited layoffs this week.  The company announced last Spring that layoffs were necessary and that employees affected by the job cuts  would be notified during the first week of December 2007. Most of the layoffs will likely occur at  BMSs' New York headquarters. Job cuts are also anticipated in sales and at several manufacturing sites.

Industry analysts believe that the company plans to announce a 10 percent to 20 percent cut in its workforce over the next three years to cut costs and save money. Also it is likely that BMS will close or sell off more than half its 38 manufacturing sites.

It has been a tough year for pharma.

Until next time....

Good Luck and Good Job Hunting....

Better than Monster: 50 Free Places You Can Post A Job Online

Amy Quinn at Bootsrapper sent me a link to a plethora of job sites where you can post your resume or if you are an employer post a job ad for free.

 

Check these sites out at:

www.businesscreditcards.com/bootstrapper/better-than-monster-50-free-places-you-can-post-a-job-online-and-get-top-talent/

 

 

Thanks Amy!

Until next time...

Good Luck and Good Job Hunting!!!!!

Happy Thanksgiving--Pharmaceutical Companies are Cutting Jobs and Closing Manufacturing Facilities in Puerto Rico

Pfizer said on Tuesday it will eliminate another 40 workers from factories in Puerto Rico. Pfizer closed a plant in Arecibo, Puerto Rico in 2005 and last year announced 210 layoffs in the U.S. Caribbean island territory

As pointed out by Ed Silverman over at Pharmalot, Puerto Rico has long been a manufacturing hub for US pharmaceutical companies. Over the past 30 years, pharmaceutical manufacturing has accounted for a quarter of the island’s gross domestic product and currently employs about 20,000 Puerto Rican citizens.

Over the past few years, companies like Watson Pharmaceuticals (generics), GlaxoSmithKline, Teva (generics), Bristol Myers Squibb and Schering Plough have either closed or will close manufacturing facilities on the Island. These closings were somewhat surprising because the Puerto Rican workforce is one of the best pharmaceutical manufacturing workforces in the world. That said, US pharmaceutical companies are looking elsewhere to produce their drugs because of rising wages, changing tax structures and the high cost of electricity (supplied by oil-fired power plants) on the island. Further, over the past decade, there have been ongoing compliance and quality assurance problems at many of the shuttered manufacturing facilities. Officials from these companies explained that it was less costly to shut down and move operations elsewhere rather than modernize the plants and bring them into regulatory compliance.

Despite these recent facility closings, the island’s pharmaceutical manufacturing industry still produces 13 of 20 best selling drugs in the US. However that number will likely continue to dwindle over the next few years. Many companies that have closed or are considering closing production facilities are moving operations to Asian destinations like Singapore, China, Thailand (and even Vietnam) where there are trained workforces, lower wages and cost structures and many people speak English.

Unlike most pharmaceutical companies, Amgen, Abbot and Lilly recently built or relocated biomanufacturing operations to Puerto Rico. Because of a trained workforce and Puerto Rico’s ongoing familiarity with FDA regulatory requirements, I suspect that other biotechnology and specialty pharmaceutical companies will consider establishing biomanufacturing facilities in Puerto Rico– pharma’s loss may well be biotech’s gain!!!!

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!

Are Medical Journals Haunted by "Ghost Writers"?

Fellow blogger, Jacob Goldstein, over at the WSJ Health Blog posted a story today about a prominent hypertension researcher who was approached by a medical communications agency about  putting her name on an abstract (she did not participate in the research) that was being prepared by the agency for a pharmaceutical client. According to the Health Blog, the researcher was so outraged by the offer that she decided to go public about the alleged “ghost writing” incident. I have no doubt that the story is accurate.  That said,  I think that a comment posted to WSJ’s blog about the story sums it all up nicely:

 “So, this is some new revelation for the WSJ? There are plenty of studies in the medical literature which have been ghost written by an industry-sponsored medical writer, that was then submitted under the name of a highly-recognizable leader in the field–always at a steep price”.

As much as I hate to admit it, the person who posted the comment is right--sort of. Although ghost writing was commonplace in the medical communications industry as recently as a few years ago, the practice is no longer tolerated at most medcom agencies, and, perhaps more importantly, by the would-be authors whose names ultimately appear on the publications. That said, medcom agencies and their clients must remain vigilant in their attempts to eradicate ghost writing entirely so that all medical communications are written (and published) in the most scientifically-sound and ethical manner.

Yes....Something Else is Wrong at Pfizer!

Talk about bad luck….Pfizer seems to have plenty. Government scientists are investigating whether Chantrix, Pfizer’s anti-smoking drug, increases suicidal thoughts and violent behavior.

FDA said that it had received reports of mood disorders and erratic behavior among patients taking Chantix, Pfizer’s prescription drug used to help quit smoking.

The agency said it was still gathering information about the drug, but advised doctors to closely monitor patients taking for behavior changes. Sales of the drug totaled $101 million last year. Small potatoes in pharma land but money nonetheless.

Pfizer has some work to do…hopefully the company can rise to the challenge.

Until Next Time….

Good Luck and Good Job Hunting

                      &

 HAPPY THANKSGIVING!!!!!!!!

Wyeth Bumps Up Its New CEO's Salary

The AP reported today that Wyeth raised the salary of its new chief executive.

President and Chief Executive Bernard Poussot will receive an annual base salary of $1.5 million, effective Jan. 1, and receive 120,000 restricted stock units that will begin to vest after three years. Poussot was promoted to CEO effective in January.  Remember, this is just Poussot's base salary.

I guess the Board of Directors felt that Bernie needed some front end incentives to keep Wyeth's stock price above $45 per share-not that there is anything wrong with that!  However, I find it troubling that executives are still getting pay raises when thousands of pharma and biotech employees are losing their jobs.  Go figure.....

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

American Biotechnology Training Buzz

I read an interesting article by G. Pascal Zachary in the Sunday Business Section of the NY times entitled “English Algebra, Phys Ed…. And Biotech”. The article focused on George Cachianes, a former Genentech researcher who became a high school teacher and the biotechnology training courses that he created at Lincoln High in the San Francisco Bay Area. Over the last 10 years, Mr. Cachianes created no fewer than 5 hands-on laboratory courses that showcase the practices and underlying principles of the biotechnology industry. In fact, each course is set up to resemble a start-up biotechnology company and is run that way by course participants! What a great experience for high school kids interested in both science and business! Great job George!!!

Biotechnology-rich regions like California, Massachusetts, Arizona, Wisconsin, Texas, North Carolina and New Hampshire were pioneers in the areas of biotechnology training and education. A quick perusal of many high school and community colleges curricula in these states reveals an extensive network of courses and certificate and associate degree programs in biotechnology. More recently, states including Virginia, Maryland and New York joined the effort. I tip my hat to the innovators in these states who had the vision to realize early on that “biotechnology was the next big thing” and that training for prospective employees was necessary for the American biotechnology industry to grow and prosper!
Continue Reading...

Are You Kidding Me-Pfizer Buys Coley Pharmaceuticals?

I guess the old adage that “You can’t teach old dogs new tricks” applies to Pfizer’s decision to buy Coley Pharmaceuticals. Why isn’t it obvious to Pfizer executives that buying companies is easy, but integrating them into a a pre-existing corporate culture is difficult, time consuming and not cost effective.

Yes, Coley is sort of a “biotechnology company” and, as Pfizer has publicly stated, it wants to get into biotech in a big way. And yes, Pfizer and Coley have had a long standing research and business partnership. But, I am not sure that Coley is going to bring any real value to Pfizer. According to Jeffrey Kindler, Pfizer’s CEO, “This acquisition is an important component of Pfizer's vaccine strategy and reflects our commitment to research new and more effective vaccines to prevent infectious diseases and to treat cancers and other debilitating conditions". Coley has been around for many years but recently re-invented itself as a biotechnology company. A quick perusal of its products indicates that is sells a vaccine adjuvant and has several drug candidates in its pipeline (with only one in early stage clinical development). Although this appears to be a quick fix to “jump start” Pfizer’s biotechnology push, I do not think the acquisition will convince business analysts and Pfizer stakeholders that Coley will allow Pfizer to boldly go where the company has not gone before!

I wish Pfizer luck! I also hope that Coley employees are updating their resumes after today’s announcement.

Until next time…

Good Luck and Good Job Hunting!!!!!

More Downsizing in Pharma Land (NJ) and Bavaria

Munich Germany based GPC Biotech announced that it was cutting 44% of its workforce in an attempt to stay in business for the next two years. Sixty jobs in Munich will be eliminated as will 43 more in Princeton, New Jersey. The company is also shutting a facility in Waltham, Massachusetts. The layoffs will leave the once high-flying German biotechnology company with 114 workers.

GPC Biotech’s troubles began in July 2007 when an FDA panel recommended delaying a decision on the experimental cancer treatment satraplatin because of doubts about clinical tests. Last month, new clinical data showed that satraplatin didn't help cancer patients live longer which resulted in the layoffs announced today.

The company will keep a core team for product development in the U.S. and Germany, and retain researchers to discover new medicines. GPC will also keep workers to support business development.

Looks like job hunting in NJ may be getting a little dicier. Oy!

Until next time….

Good Luck and Good Job Hunting!!!!!!!

Update: Johnson & Johnson Creates New Divisions but Job Cuts Continue

Johnson & Johnson announced a “series of organizational changes, including the creation of a new strategy and growth organization to sharpen its focus on opportunities outside its traditional areas of interest and in the growing intersections of health care and the creation of two new business operating groups.”

Scott Hensley over at the WSJ Health Blog wrote “It’s no secret that the diversified health-products giant faces some gargantuan challenges. Sales of anemia drugs, for years the company’s biggest franchise, have been under intense pressure. Stents, another J&J hallmark, are hurting”.

J&J announced a plan last July to cut 3% to 4% of its roughly 122,000-person work force or approximately 4,820 jobs. According to my colleagues at J & J, job cuts have been taking place since the announcement and will continue into 2008.

Times are certainly tough for the life sciences industry. Is this a harbinger of things to come for other sectors of the US economy? I hope not…..

Until next time….

Good luck and Good Job Hunting!

Watch Out Amgen: Roche's EPO-like Drug Mircera Gains FDA Approval

Swiss pharmaceuticals producer Roche Holding AG said Thursday it has received approval from the U.S. health authorities for its anemia drug Mircera, but is still awaiting resolution of a patent case before launching the drug in the United States.

Mircera, which has been approved by the U.S. Food and Drug Administration for patients with anemia caused by kidney failure, is the subject of a legal tussle between Roche and rival Amgen Inc.

The new EPO-like drug is already sold in Austria, Sweden, Germany, Britain and Norway, Roche said.

Amgen will fight Roche to the end on this one. But, I think Roche will prevail. Let’s hope so!!!!!!!

Hot Off the Press: "May Cause Heart Attack" Added to GSK's Avandia Label

The FDA ruled today that GlaxoSmithKline’s blockbuster diabetes drug Avandia will now carry as part of its label a warning advising that its use might raise the risk of suffering a heart attack.

A black box warning is the sternest warning a drug can carry and still remain on the market in the U.S. Avandia already carries a black box warning advising it could cause or exacerbate congestive heart failure in some patients.

With 2006 sales of almost $3 billion, Avandia has been a major revenue driver for Glaxo.

Look for continued corporate right sizing at GSK through 2008.

Until next time….

Good Luck and Good Job Hunting!!!!!!!!

Another Bad Investment for Pfizer -Inhaled PEGylated Human Growth Hormone

I was reading a post about the Exubera deal that Pfizer cut with Nektar the other day and I stumbled upon this tidbit–“The two companies will continue to jointly develop an inhaled formulation of PEGylated recombinant human growth hormone (rHGH) to treat growth problems”.

For those of you who may not know, protein PEGylation–developed about 30 years ago by Frank Davis and Abe Abuchowski at Rutgers University– involves chemically attaching polyethylene glycol (PEG) to proteins. PEGylated proteins are less immunogenic and circulate longer in the bloodstream than native, unPEGylated proteins. Protein PEGylation has revolutionized the biopharmaceutical industry because it reduces immunological side effects, improves clinical efficacy and enhances patient compliance (by reducing the number of injections that are required) for many protein-based drugs. Several companies including Schering Plough, Roche and Amgen have used protein PEGylation to create multibillion blockbuster a year biotechnology products like PEG-Intron, Pegasys and Neulasta.

Like most protein-based products, rHGH needs to be injected daily to achieve its desired clinical effects. At present, there are no fewer than 8 rHGH products on the market that are used to treat pediatric and adult growth hormone deficiencies. The holy grail of the growth hormone market is to develop a sustained-release version of rHGH so that daily injections are no longer necessary. To that end, several companies, including Nektar, have developed PEGylated versions of rHGH which are in various stages of clinical development. These products should hit the markets in Europe and the US within the next few years.

Although Pfizer is in the rHGH biz, it is puzzling (to me) why any company would consider developing an inhaled form of PEGylated rHGH –given all of the regulatory hurdles and exhorbitant development costs-when an injectable form of PEGylated rHGH would be far superior and offer greater patient benefits than any of the currently marketed rHGH products? Maybe I am missing something here. That said, the larger question is: Why hasn’t Pfizer learned that the inhaled protein market is a dicey one at best?  Maybe that's why Pfizer is still Pfizer!

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!!!

Amgen Slapped with Two Federal Subpoenas

The NY Times reported today that Amgen has disclosed that it recently received two federal subpoenas seeking documents related to its products Neupogen, Neulasta and Aranesp.

In a quarterly report with the Securities and Exchange Commission, the company said it intended to cooperate in responding to the subpoenas, issued by the United States attorneys’ offices for the Eastern District of New York and Western District of Washington.

Amgen also disclosed that it was sued in New Jersey this month by the Sheet Metal Workers National Health Fund.

According to the S.E.C. filing, the lawsuit says Amgen engaged in an “anticompetitive tying arrangement and pricing scheme” involving the sale of Neupogen and Neulasta, used against the side effects of chemotherapy, and Aranesp, an anemia drug.

It is becoming increasingly difficult to maintain a monopoly in this country…Go figure!!!

Until Next Time

Just As I Suspected!!!!

I want to thank Ed Silverman over at Pharmalot for providing me with data to back up my suspicions that hiring is taking a downturn at most pharmaceutical, biotechnology and medical devices companies.

According to the post at Pharmalot “Employers and recruiters in pharma, health care and biotech performed fewer searches in October, mostly thanks to declines in two key states - New Jersey and Massachusetts, which dropped by 5.6 and 3.2 percent, respectively, according to stats from MedZilla.com. Of the top jobs posted, the biggest changes were in research (a loss of two percent) and gains of 1.8 to 2.3 percent in business development, primary care, and marketing. Applicants, meanwhile, continued at the previous month’s rate of job searching, with only California seeing a change of more than one percent in either direction.”

Sales jobs are also taking a big hit.

I hate to be the bearer of bad news but sometimes a reality check is necessary to maintain perspective.

Keep the faith!

Until next time…

Good Luck and Good Job Hunting!!!!!!

Merck Executives Finally Succumb to Vioxx Pressure-Or Do They?

Finally, three years after withdrawing its pain medication Vioxx from the market, Merck announced today that it will pay $4.85 billion to settle 27,000 lawsuits by people who believe they or their family members suffered injury or died after taking the drug. The settlement, one of the largest ever in civil litigation, comes after nearly 20 Vioxx civil trials over the last two years from New Jersey to California.

In 2005, most Wall Street analysts estimated that Merck’s ultimate liability in Vioxx would be between $10 billion and $25 billion after plaintiffs announced that they would file lawsuits against Merck. Merck stunned just about everyone in the industry by not settling and announcing that it would fight each Vioxx lawsuit one-by-one. In hindsight, this was a brilliant legal strategy. As you may recall, Merck’s stock price plummeted to the mid $20s shortly after the Vioxx scandal broke. After Merck implemented its legal strategy–and won a few lawsuits after a crushing initial defeat–its stock price began to steadily rise. Merck's stock closed yesterday at almost $55 per share–it is up about 5% today in early trading.

Although one of the largest ever, the settlement payment represents less than one year’s profits for the company. The agreement is far smaller than Wall Street analysts and lawyers predicted when Merck withdrew Vioxx, and especially after the verdict in the first case. By agreeing to settle, Merck will be able to get past the Vioxx debacle and also sharply reduce its Vioxx-related legal defense fees, which are now running at more than $600 million annually.

I must admit that I was one of the many who thought that Merck was making a big mistake by not settling all of the Vioxx lawsuits. It just goes to show you that some of these well paid pharmaceutical executives actually know what they are doing.

Maybe that's why Merck is still hiring and its competitors’ are not?????

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!

Cephalon Gets Whacked For Illegal Marketing and Sales Practices

When are drug companies going to learn that monopolies are illegal in the US? The New York Times reported today that Pennsylvania-based Cephalon, the maker of sleep and pain drugs, has agreed to pay $425 million to settle a federal investigation into its sales and marketing practices.

The company, maker of the sleep-disorder drug Provigil, was sued by the Pennsylvania Turnpike Commission in May over claims that the company sought to monopolize the drug market by delaying generic competition. Delaying generic competition? Sound familiar? You may want to ask Peter Dolan, former CEO of Bristol-Myers Squibb about his experiences with preventing generic competition for Plavix. I am sure you will get an earful.

Keep an eye on Cephalon for possible layoffs.

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!!

Sepracor to Cut 300 Sales Jobs

The Marlborough, Mass.-based drugmaker Sepracor announced last week that it would cut 300 sales job due to poor third quarter earnings.  Revenue for the quarter fell 1.9% to $283.95 million.

Sepracor manufactures and sells the well known sleep aid Lunesta which jumped 14% to $160.9 million from last year. However, sales of its respiratory product Xopenex HCL Inhalation Solution slid from $125.4 million to $94.4 million. The company announced the layoffs to reduce costs.

Looks like things are starting to slow down in the Boston area.

Until next time....

Good Luck and Good Job Hunting!!!!!!!!!!!!!

Boston Scientific Begin Asset Allocation Realignment aka Downsizing

I want to thank Ed Silverman over at thePharmalot blog for alerting me that Boston Scientific has begun its promised corporate downsizing to save half a billion dollars a year.

The company began the process of laying off Minnesota workers Tuesday, according to media reports, although just how many workers have received notice is not known. A report in the Star Tribune cited an internal memo to workers dated Oct. 5, detailing that workers whose positions would be eliminated would receive 60 days notice.

A spokesman for the company said Wednesday morning that the company could not confirm if or how many Minnesota workers had been given notice that their positions would be eliminated.

The company said in February it would lay off between 500 and 600 people at its Arden Hills facility. About 2,000 employees are expected to leave the company due to previously announced restructuring moves.

Boston Scientific has said for months that it would make substantial changes to its business, including monetizing its investment portfolio and cutting its workforce.

Published November 7, 2007 by the Minneapolis / St. Paul Business Journal


Find Diversity employment at DiversityJobs.com.

Finally-A Reality Check at Momenta Pharmaceuticals

The Massachusetts-based biotechnology company, Momenta Pharmaceuticals, announced late yesterday that FDA refused to approve its ANDA filing for M-Enoxaparin, a generic version of Sanofi-Aventis' Lovenox®. The agency cited that Momenta had failed to provide data in its application on the potential immunogenicity of M-Enoxaparin. I find this oversight to be extremely perplexing because Momenta’s management team had to know that regulatory approval of a product –considered to be a follow-on biologic (M-Enoxaparin is a synthetic version of low molecular weight heparin which is a polysaccharide) – would require a rigorous assessment of the product's  potential immunogenicity. If Momenta did not know about the immunogenicity requirements, then Sandoz (its co-development partner) had to be keenly aware of them because Sandoz had to provide immunogenicity data to FDA to garner approval last year of Omnitrope®, a follow-on version of human recombinant growth hormone (rHGH).

Although FDA’s refusal to approve M-Enoxaprin is a setback for the follow-on biologics movement in the US, it is about time, in my opinion, that Momenta’s stock price truly reflects the real market value of the company. Much to my surprise, Momenta’s stock price was over $30 a share about two years ago– presumably founded in the notion that the company’s innovative carbohydrate technology platform could be used to create a generic version of Sanofi’s multi billion dollar a year Lovenox® . I have no doubt that Momenta’s technology platform is one of the more innovative ones in the carbohydrate synthesis biz. However, as a former employee of 2 biotech companies founded on revolutionary carbohydrate synthesis platforms, I think that Momenta’s elevated stock price had more to do with the pedigree of scientists who started the company and the ROI that these scientists previously provided to the VCs who are currently backing Momenta. Further, cutting a deal with Sandoz, a company whose name is now synonymous with follow-on biologics may also have contributed to the elevated stock price.

If I was one of Momenta 100 or so employees I would be dusting off that resume right about now.

Unitl next time....

Good Luck and Good Job Hunting!!!!!!

What Does Unmet Medical Need Really Mean in "Pharma Speak"?

Every major pharmaceutical company on the planet declares that it “invests billions of dollars into R &D to develop novel medicines to address unmet medical needs”. Further, pharmaceutical company advocates and lobbyists frequently justify the high costs of medicines by suggesting that they are necessary because companies must reinvest a portion of their profits into R & D to discover new drugs. After receiving several comments posted to BioJobBlog informing me that high drug prices are necessary in order for pharma companies to continue to meet unmet medical needs, I decided to delve a little deeper into what “addressing unmet medical needs” really means in the pharmaceutical industry.

My personal favorite that seems to fit pharma’s interpretation of “addressing unmet medical needs” is the development of no fewer than 3 medications (Viagra®, Levitra® and Cialis®, with several more in clinical trials) to treat erectile dysfunction (ED). For those of you who don’t know, all three drugs have almost identical mechanisms of action. Who knew that so many men had this serious, potentially life-threatening medical condition? Don’t get me wrong–there are men that must take these drugs to …well…rise to the occasion. That said, pharmaceutical marketers realized early on, that this class of drugs could yield billions of dollars–not necessarily as ED treatments (the number of men who actually suffer from ED is relatively small) – but as recreational drugs to enhance male sexual performance. The booming sales figures for these drugs indicate that the pharmaceutical marketers were absolutely spot on in their thinking. Thanks to these pioneering medical marketers men all over the world no longer have to fret about dying or succumbing to the perils of ED.



Continue Reading...

Being Smart is Not Always Enough

The firestorm that was ignited by the seemingly racist remarks made by Nobel Laureate James Watson several weeks ago started me thinking about scientists and the way that they are trained. In general, scientists emphasize and place an inordinately high premium on “being smart”. If graduate students or postdoctoral fellows are deemed to be “really smart”, their mentors tend to overlook inappropriate or, in some instances, antisocial behavior.  Further, and perhaps more egregiously, they do little to help these students and postdocs overcome or correct their in appropriate or bad behavior. Consequently, these individuals continue to behave inappropriately and believe that, because they are smart, they can do or say whatever they want without fear of punishment or retribution. 

 

I can recall a conversation that I had as a postdoctoral fellow during a visit with an award-winning faculty member from my old department about a faculty member (let’s call him Dr. X) who worked in the department where I was doing my postdoctoral work. During our conversation, I mentioned that Dr. X treated his people badly and frequently humiliated them at departmental meetings and social gatherings. I will never forget what she said in response to my remarks–“Yes, everyone knows that Dr. X has problems and he treats his graduate students and postdoctoral fellows badly, but he is brillant and so successful that people are willing to overlook his shortcomings”.  As I look back, this conversation had a greater impact on my career than I care to acknowledge.

 

During my 7 years as a tenure-track Assistant Professor, I totally bought into the notion that being smart is all that matters. I expected people to give me the benefit of any doubt even though I may have acted inappropriately or behaved badly in certain situations. Unfortunately, after I left academia ( fro the record-I was smart enough), and began working in the "real world", I discovered the hard way that being smart is simply not enough to keep a job or advance a career.

 

As I see it, Watson is just another casualty in a long list of world-renown scientists who finally pushed the limits of civility and tolerance to a breaking point and justly received what he deserved-- an appropriate punishment that, many feel, was long overdue. I think that the Watson spectacle ought to be a wake up call for the folks who are currently training the next generation of scientists—being smart is certainly important but it is simply not enough to insure a long, successful and untainted scientific career.

 

Until next time....

 

Good Luck and Good (Smart?) Job Hunting !!!!!!!!!! 

Physicians Still Have Clout: Genentech Scuttles Plans to Limit Avastin Use to Treat Eye Disease

Genentech announced yesterday that it is delaying a plan that would have limited the use of its cancer drug Avastin to treat wet macular degeneration. Earlier this month, Genentech unveiled plans to ban purchases of Avastin by independent compounding pharmacies to prevent them from creating smaller doses of the drug that can be used by ophthalmologists to treat wet macular degeneration.  By banning sales of Avastin to these pharmacies, Genentech sought to force ophthalmologists to use Lucentis($2,000 per dose) in lieu of Avastin –which is (40 to 50 times lower than a comparable dose of Lucentis–to treat eye disease. Lucentis, which was recently approved to treat wet macular degeneration, and Avastin®, have very similar mechanisms of action.

 

The company acted to reinstate it supply of Avastin to compounding pharmacies after senior Genentech officials met with the American Academy of Ophthalmology and American Society of Retina Specialists. I guess doctors still have some clout over the disingenuous practices of some drug companies.

 

The FDA also weighed in on the dispute and reiterated in a statement that the agency did not previously ask Genentech to stop distributing Avastin to compounding pharmacies and that it has not taken any action to limit the off-label use of Avastin to treat wet macular degeneration.

Don’t you just love it when drug companies try to blame FDA for their failed avaricious plans to increase corporate profits and bolster their stock prices?

 

Until next time…

 

Good Luck and Good Job Hunting